Revolutionizing Drug Delivery: Molecular Syringes and Programmable Protein Injection Systems

MIT CRISPR researcher Feng Zhang and his lab have engineered syringes made by bacteria to deliver potential therapies like toxins that kill cancer cells and gene editors. They developed syringes that can load proteins of their choice and selectively target human cells. Meanwhile, Johnson & Johnson has ended development of its adult RSV vaccine that was in the middle of a 27,200-patient trial, giving up a big slice of what’s expected to be the next multibillion-dollar pharma market. The FDA has approved Emergent BioSolutions’ Narcan brand naloxone nasal spray for over the counter sales.